Correspondence 0001193125-24-143282 from Mereo BioPharma Group plc (MREO) (CIK 0001719714) (MREO)
Mereo BioPharma Group plc (MREO) (CIK 0001719714)
Date: May 21, 2024 · CIK: 0001719714 · Accession: 0001193125-24-143282
AI Filing Summary & Sentiment
File numbers found in text: 333-279433
Letter
Mereo BioPharma Group plc
Fourth Floor
One Cavendish Place
London W1G 0QF
United Kingdom
May 21, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C.
Attention:
Division of Corporation Finance
Office of Life Sciences
Re:
Mereo BioPharma Group plc
Registration Statement on Form S-3
Filed on May 15, 2024
File No. 333-279433
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Mereo BioPharma Group plc (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced registration statement on Form S-3 (the “Registration Statement”) so that the Registration Statement will be declared effective as of 4:00 p.m., Eastern Time, on May 22, 2024, or at such other time as the Company or its outside counsel, Mayer Brown LLP, may request via a telephone call to the staff of the Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with David S. Bakst of Mayer Brown LLP at (212) 506-2551.
Thank you for your assistance in this matter.
Very truly yours,
MEREO BIOPHARMA GROUP PLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP Mereo BioPharma Group plc Fourth Floor One Cavendish Place London W1G 0QF United Kingdom May 21, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Division of Corporation Finance Office of Life Sciences Re: Mereo BioPharma Group plc Registration Statement on Form S-3 Filed on May 15, 2024 File No. 333-279433 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Mereo BioPharma Group plc (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced registration statement on Form S-3 (the “Registration Statement”) so that the Registration Statement will be declared effective as of 4:00 p.m., Eastern Time, on May 22, 2024, or at such other time as the Company or its outside counsel, Mayer Brown LLP, may request via a telephone call to the staff of the Commission. Once the Registration Statement has been declared effective, please orally confirm that event with David S. Bakst of Mayer Brown LLP at (212) 506-2551. Thank you for your assistance in this matter. Very truly yours, MEREO BIOPHARMA GROUP PLC By: /s/ Denise Scots-Knight Name: Denise Scots-Knight Title: Chief Executive Officer Cc: David S. Bakst Mayer Brown LLP Christine Fox Charles Sermon Mereo BioPharma Group plc